Investigator Initiated Study (IIS)

Dermavant supports investigator/externally led research programs related to Dermavant’s compounds and relevant therapeutic areas of interest.

The objectives of these programs are to:

  • Advance clinical and pre-clinical research
  • Generate health outcomes data and real-world evidence
  • Enhance disease understanding and medical knowledge that may lead to improvements in clinical care

These programs are open to healthcare providers, researchers and institutions interested in conducting external research within countries in which Dermavant has obtained regulatory approval.

Investigators and/or their affiliated institutions and networks assume responsibility for all aspects of the study, including design, regulatory submission, initiation, conduct, and monitoring of the research, along with data analysis and communication (e.g. abstract, manuscript, and final study report) of the results.

Proposals submitted to Dermavant are reviewed by Dermavant's scientific and medical committee. Approval of a proposal is based on alignment with Dermavant's IIS areas of interest, scientific merit, patient safety considerations, unmet medical need, study design, availability of resources, and feasibility of study conduct. Support for approved proposals may be provided in the form of study drug supply, funding, or both depending on the request, and is contingent upon a final approved protocol, regulatory clearance, Investigator Review Board approval, and full execution of a research agreement.

Current IIS areas of interest:

  • Clinical studies focused on generation of data to provide clinicians further information on the role and appropriate use of tapinarof for the treatment of plaque psoriasis
  • Studies to help advance understanding of the aryl hydrocarbon receptor (AhR) and its potential role in the treatment of inflammatory disorders
  • Real-world evidence and health-outcomes data generation on tapinarof
  • Case series or clinical data analyses evaluating real-world use and outcomes associated with tapinarof for the treatment of plaque psoriasis
  • Studies designed to assess burden and gaps in the treatment of plaque psoriasis and atopic dermatitis

Dermavant IIS Concept Application

Please submit all IIS proposals and / or inquiries via email at